Table 4.
Characteristics of the patients, observed by RT-PCR, treatment, and laboratory parameters; categorical data: n (%).
| Parameters | Influenza A (H1N1) 2022–2023 Season n (%) 608 (86.4) |
Influenza A (H3N2) 2022–2023 n (%) 96 (13.6) |
Influenza B 2022–2023 n (%) 87 (11) |
Influenza A (H1N1) 2023–2024 n (%) 346 (83.4%) |
Influenza A (H3N2) 2023–2024 n (%) 69 (16.6%) |
Influenza B 2023–2024 n (%) 94 (18.4%) |
p-Value |
|---|---|---|---|---|---|---|---|
| Treatment n (%) | |||||||
| Duration of hospitalization days n (IQR) | 5 (3–6) | 4 (2–5) | 7 (1–7) | 5 (4–6) | 4 (3–5) | 6 (2–6) | 0.01 |
| Oseltamivir | 402 (66.12) | 59 (61.46) | 39 (44.83) | 214 (61.85) | 17 (24.64) | 18 (19.15) | 0.001 |
| Oseltamivir and dexamethasone | 124 (20.4) | 22 (22.91) | 31 (35.63) | 49 (14.16) | 29 (42.65) | 14 (14.89) | 0.11 |
| Oseltamivir, dexamethasone and antibiotics | 82 (13.49) | 15 (15.63) | 27 (31.03) | 83 (24) | 41 (42.03) | 32 (34.04) | 0.001 |
| Laboratory n (%) | |||||||
| AST, U/L > 5× normal values | 124 (20.39) | 76 (60.32) | 38 (67.86) | 24 (6.94) | 12 (17.39) | 36 (53) | 0.05 |
| ALT, U/L > 5× normal values | 136 (22.37) | 89 (92.71) | 45 (51.72) | 42 (12.14) | 43 (62.32) | 21 (22.34) | 0.01 |
| Hemoglobin | 216 (35.53) | 70 (55.5) | 36 (64.3) | 22 (6.36) | 29 (42.03) | 32 (47.1) | 0.001 |
| Leukocyte | 112 (18.42) | 67 (69.79) | 65 (74.71) | 24 (6.94) | 56 (81.16) | 18 (19.15) | 0.31 |
| Lymphopenia | 98 (16.12) | 34 (27) | 21 (37.5) | 14 (4.05) | 17 (24.64) | 12 (17.6) | 0.32 |
| Neutrophilia | 109 (17.93) | 23 (23.96) | 11 (12.64) | 32 (9.25) | 23 (33.33) | 13 (13.83) | 0.1 |
| Low Thrombocyte | 98 (16.12) | 37 (29.4) | 14 (25) | 33 (9.54) | 35 (50.74) | 21 (30.9) | 0.11 |
| High Prothrombin time | 123 (20.23) | 76 (60.32) | 44 (78.6) | 21 (6.07) | 29 (42.03) | 30 (44.12) | 0.23 |
| LDH elevated | 234 (38.49) | 51 (40.5) | 28 (50) | 40 (11.56) | 32 (46.38) | 22 (32.35) | 0.31 |
| CRP elevated | 112 (18.42) | 55 (43.65) | 32 (57.14) | 42 (12.14) | 44 (63.77) | 21 (30.88) | 0.021 |